Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma.

Vuolo F, Abreu SC, Michels M, Xisto DG, Blanco NG, Hallak JE, Zuardi AW, Crippa JA, Reis C, Bahl M, Pizzichinni E, Maurici R, Pizzichinni MMM, Rocco PRM, Dal-Pizzol F.

Eur J Pharmacol. 2018 Nov 24;843:251-259. doi: 10.1016/j.ejphar.2018.11.029. [Epub ahead of print]

PMID:
30481497
2.

Acute effects of ayahuasca in a juvenile non-human primate model of depression.

da Silva FS, Silva EAS, Sousa GM Jr, Maia-de-Oliveira JP, Soares-Rachetti VP, de Araujo DB, Sousa MBC, Lobão-Soares B, Hallak J, Galvão-Coelho NL.

Braz J Psychiatr. 2018 Nov 8:0. doi: 10.1590/1516-4446-2018-0140. [Epub ahead of print]

3.

Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans: Preliminary Evidence of Interactive Effects of Ayahuasca and Endocannabinoids in a Healthy Human Subject.

Dos Santos RG, Crippa JA, Osório FL, Rocha JM, Rossi GN, Marchioni C, Queiroz MEC, Silveira GO, Yonamine M, Hallak JEC.

J Clin Psychopharmacol. 2018 Dec;38(6):644-646. doi: 10.1097/JCP.0000000000000973. No abstract available.

PMID:
30339603
4.

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia.

Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak JEC, Crippa JA, Abílio VC.

Front Pharmacol. 2018 Aug 21;9:901. doi: 10.3389/fphar.2018.00901. eCollection 2018.

5.

Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload.

da Silva VK, de Freitas BS, Garcia RCL, Monteiro RT, Hallak JE, Zuardi AW, Crippa JAS, Schröder N.

Transl Psychiatry. 2018 Sep 3;8(1):176. doi: 10.1038/s41398-018-0232-5.

6.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F.

CNS Drugs. 2018 Aug;32(8):697-712. doi: 10.1007/s40263-018-0550-4.

PMID:
30109642
7.

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.

Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC.

Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902. doi: 10.1080/17512433.2018.1511424. Epub 2018 Aug 23. Review.

PMID:
30102078
8.

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, Dos Santos RG, Tófoli LF, de Oliveira Silveira G, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvão-Coelho NL, Lobão-Soares B, Hallak JEC, Arcoverde E, Maia-de-Oliveira JP, Araújo DB.

Psychol Med. 2018 Jun 15:1-9. doi: 10.1017/S0033291718001356. [Epub ahead of print]

PMID:
29903051
9.

Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos.

Valim Brigante TA, Abe FR, Zuardi AW, Hallak JEC, Crippa JAS, de Oliveira DP.

Chem Biol Interact. 2018 Aug 1;291:81-86. doi: 10.1016/j.cbi.2018.06.008. Epub 2018 Jun 11.

PMID:
29902416
10.

Alterations in the stomatognathic system due to amyotrophic lateral sclerosis.

Gonçalves LMN, Palinkas M, Hallak JEC, Marques Júnior W, Vasconcelos PB, Frota NPR, Regalo IH, Siéssere S, Regalo SCH.

J Appl Oral Sci. 2018 Jun 11;26:e20170408. doi: 10.1590/1678-7757-2017-0408.

11.

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC.

Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018. Review.

12.

Psychedelics and Personality.

Aixalà M, Dos Santos RG, Hallak JEC, Bouso JC.

ACS Chem Neurosci. 2018 Oct 17;9(10):2304-2306. doi: 10.1021/acschemneuro.8b00237. Epub 2018 Jun 4.

PMID:
29863323
13.

An Overview of Animal Models Related to Schizophrenia.

Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, Hallak J, Howland JG.

Can J Psychiatry. 2018 Jan 1:706743718773728. doi: 10.1177/0706743718773728. [Epub ahead of print]

PMID:
29742910
14.

No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, Hallak JE, Crippa JAS.

Front Pharmacol. 2018 Apr 5;9:315. doi: 10.3389/fphar.2018.00315. eCollection 2018.

15.

Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Diana MC, Peres FF, Justi V, Bressan RA, Lacerda ALT, Crippa JA, Hallak JEC, Abilio VC.

CNS Neurosci Ther. 2018 Jul;24(7):624-632. doi: 10.1111/cns.12852. Epub 2018 Apr 14.

PMID:
29656549
16.

Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model.

Callejas GH, Figueira RL, Gonçalves FLL, Volpe FAP, Zuardi AW, Crippa JA, Hallak JE, Sbragia L.

Braz J Med Biol Res. 2018 Mar 15;51(5):e7132. doi: 10.1590/1414-431X20177132.

17.

Male Sexual Quality Of Life Is Maintained Satisfactorily Throughout Life In The Amazon Rainforest.

Teixeira T, Nazima M, Hallak J.

Sex Med. 2018 Jun;6(2):90-96. doi: 10.1016/j.esxm.2017.11.002. Epub 2018 Mar 6.

18.

Author Correction: Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.

Lawn W, Hallak JE, Crippa JA, Dos Santos R, Porffy L, Barratt MJ, Ferris JA, Winstock AR, Morgan CJA.

Sci Rep. 2018 Mar 1;8(1):4059. doi: 10.1038/s41598-018-21666-6.

19.

Serotonergic psychedelics and personality: A systematic review of contemporary research.

Bouso JC, Dos Santos RG, Alcázar-Córcoles MÁ, Hallak JEC.

Neurosci Biobehav Rev. 2018 Apr;87:118-132. doi: 10.1016/j.neubiorev.2018.02.004. Epub 2018 Feb 13. Review.

PMID:
29452127
20.

Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study.

Kang KB, Karas FI, Rai R, Hallak JA, Kang JJ, de la Cruz J, Cortina MS.

PLoS One. 2018 Feb 6;13(2):e0192381. doi: 10.1371/journal.pone.0192381. eCollection 2018.

21.

Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol.

da Silva VK, de Freitas BS, Dornelles VC, Kist LW, Bogo MR, Silva MC, Streck EL, Hallak JE, Zuardi AW, Crippa JAS, Schröder N.

Brain Res Bull. 2018 May;139:1-8. doi: 10.1016/j.brainresbull.2018.01.014. Epub 2018 Jan 31.

PMID:
29374603
22.

Ayahuasca: Psychological And Physiologic Effects, Pharmacology And Potential Uses In Addiction And Mental Illness.

Hamill J, Hallak J, Dursun SM, Baker G.

Curr Neuropharmacol. 2018 Jan 24. doi: 10.2174/1570159X16666180125095902. [Epub ahead of print]

PMID:
29366418
23.

Lipopolysaccharide and lipotheicoic acid differentially modulate epididymal cytokine and chemokine profiles and sperm parameters in experimental acute epididymitis.

Silva EJR, Ribeiro CM, Mirim AFM, Silva AAS, Romano RM, Hallak J, Avellar MCW.

Sci Rep. 2018 Jan 8;8(1):103. doi: 10.1038/s41598-017-17944-4.

24.

Brain functional and perfusional alterations in schizophrenia: an arterial spin labeling study.

Oliveira ÍAF, Guimarães TM, Souza RM, Dos Santos AC, Machado-de-Sousa JP, Hallak JEC, Leoni RF.

Psychiatry Res Neuroimaging. 2018 Feb 28;272:71-78. doi: 10.1016/j.pscychresns.2017.12.001. Epub 2017 Dec 5.

PMID:
29229240
25.
26.

Retroprosthetic Membrane Formation in Boston Keratoprosthesis: A Case-Control-Matched Comparison of Titanium Versus PMMA Backplate.

Talati RK, Hallak JA, Karas FI, de la Cruz J, Cortina MS.

Cornea. 2018 Feb;37(2):145-150. doi: 10.1097/ICO.0000000000001462.

PMID:
29140862
27.

Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.

Lawn W, Hallak JE, Crippa JA, Dos Santos R, Porffy L, Barratt MJ, Ferris JA, Winstock AR, Morgan CJA.

Sci Rep. 2017 Nov 9;7(1):15201. doi: 10.1038/s41598-017-14700-6. Erratum in: Sci Rep. 2018 Mar 1;8(1):4059.

28.
29.

Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.

Ruggiero RN, Rossignoli MT, De Ross JB, Hallak JEC, Leite JP, Bueno-Junior LS.

Front Pharmacol. 2017 Jun 21;8:399. doi: 10.3389/fphar.2017.00399. eCollection 2017. Review.

30.

Ayahuasca intoxication.

Dos Santos RG, Bouso JC, Hallak JEC.

Med Clin (Barc). 2017 Nov 22;149(10):461-462. doi: 10.1016/j.medcli.2017.04.032. Epub 2017 Jun 15. English, Spanish. No abstract available.

PMID:
28622996
31.

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.

Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa JAS.

Front Pharmacol. 2017 May 11;8:259. doi: 10.3389/fphar.2017.00259. eCollection 2017.

32.

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Dos Santos RG, Bouso JC, Hallak JEC.

Ther Adv Psychopharmacol. 2017 Apr;7(4):141-157. doi: 10.1177/2045125316689030. Epub 2017 Feb 23. Review.

33.

Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities.

Sampedro F, de la Fuente Revenga M, Valle M, Roberto N, Domínguez-Clavé E, Elices M, Luna LE, Crippa JAS, Hallak JEC, de Araujo DB, Friedlander P, Barker SA, Álvarez E, Soler J, Pascual JC, Feilding A, Riba J.

Int J Neuropsychopharmacol. 2017 Sep 1;20(9):698-711. doi: 10.1093/ijnp/pyx036.

34.

Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy.

Do Val-da Silva RA, Peixoto-Santos JE, Kandratavicius L, De Ross JB, Esteves I, De Martinis BS, Alves MN, Scandiuzzi RC, Hallak JE, Zuardi AW, Crippa JA, Leite JP.

Front Pharmacol. 2017 Mar 17;8:131. doi: 10.3389/fphar.2017.00131. eCollection 2017.

35.

Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings.

Chagas MHN, Tumas V, Pena-Pereira MA, Machado-de-Sousa JP, Carlos Dos Santos A, Sanches RF, Hallak JEC, Crippa JAS.

J Psychiatr Res. 2017 Jul;90:40-45. doi: 10.1016/j.jpsychires.2017.02.010. Epub 2017 Feb 13.

PMID:
28222355
36.

Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?

Maia-de-Oliveira JP, Baker GB, Dursun SM, Hallak JE.

Psychol Med. 2017 Apr;47(5):981-982. doi: 10.1017/S003329171600307X. Epub 2016 Dec 9. No abstract available.

PMID:
27931266
37.

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU.

Am J Psychiatry. 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503. Epub 2016 Dec 6. Review.

38.

Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies.

Dos Santos RG, Hallak JE.

J Psychoactive Drugs. 2017 Jan-Mar;49(1):1-10. doi: 10.1080/02791072.2016.1260189. Epub 2016 Dec 5. Review.

PMID:
27918874
39.

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging.

Dos Santos RG, Osório FL, Crippa JAS, Hallak JEC.

Neurosci Biobehav Rev. 2016 Dec;71:715-728. doi: 10.1016/j.neubiorev.2016.10.026. Epub 2016 Oct 31. Review.

PMID:
27810345
40.

Nitric Oxide's Involvement in the Spectrum of Psychotic Disorders.

Maia-de-Oliveira JP, Kandratavicius L, Nunes EA, Machado-de-Sousa JP, Hallak JE, Dursun SM.

Curr Med Chem. 2016;23(24):2680-2691. Review.

PMID:
27450675
41.

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.

Crippa JA, Crippa AC, Hallak JE, Martín-Santos R, Zuardi AW.

Front Pharmacol. 2016 Sep 30;7:359. eCollection 2016.

42.

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Peres FF, Levin R, Suiama MA, Diana MC, Gouvêa DA, Almeida V, Santos CM, Lungato L, Zuardi AW, Hallak JE, Crippa JA, Vânia D, Silva RH, Abílio VC.

Front Pharmacol. 2016 Sep 28;7:343. eCollection 2016.

43.

Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC.

Front Pharmacol. 2016 Sep 9;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016. Review.

44.

Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.

PLoS One. 2016 Aug 25;11(8):e0162087. doi: 10.1371/journal.pone.0162087. eCollection 2016.

45.

Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases.

Batista-Filho MM, Kandratavicius L, Nunes EA, Tumas V, Colli BO, Hallak JE, Maia-de-Oliveira JP, Evora PR.

CNS Neurol Disord Drug Targets. 2016;15(8):976-986. Review.

PMID:
27450870
46.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.

PLoS One. 2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162087.

47.

Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness.

Torres US, Duran FL, Schaufelberger MS, Crippa JA, Louzã MR, Sallet PC, Kanegusuku CY, Elkis H, Gattaz WF, Bassitt DP, Zuardi AW, Hallak JE, Leite CC, Castro CC, Santos AC, Murray RM, Busatto GF.

Neuroimage Clin. 2016 Jun 3;12:1-15. doi: 10.1016/j.nicl.2016.06.002. eCollection 2016.

48.

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE.

Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213. doi: 10.1177/2045125316638008. Epub 2016 Mar 18. Review.

49.

The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging.

Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE.

J Psychopharmacol. 2016 Dec;30(12):1230-1247. Epub 2016 Jun 10. Review.

PMID:
27287824
50.

Supplemental Content

Loading ...
Support Center